moatshark My

All holdings

Vanda Pharmaceuticals

VNDA

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
1
In their latest 13F (Q3 2026)
See who
Value held
$139k
Combined value at quarter end
Last quarter
0 bought
1 sold or trimmed
Price at Q2 ’26 end
$6.12
-11.4% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

-17.0%Q3 ’24
+2.1%Q4 ’24
-4.2%Q1 ’25
+2.8%Q2 ’25
+5.7%Q3 ’25
+76.8%Q4 ’25
-21.7%Q1 ’26
-11.4%Q2 ’26
Q3 ’24: -17.0%; Q4 ’24: +2.1%; Q1 ’25: -4.2%; Q2 ’25: +2.8%; Q3 ’25: +5.7%; Q4 ’25: +76.8%; Q1 ’26: -21.7%; Q2 ’26: -11.4%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

1Q4 ’23
1Q1 ’24
1Q2 ’24
1Q3 ’24
1Q4 ’24
1Q1 ’25
1Q2 ’25
1Q3 ’25
1Q4 ’25
1Q1 ’26
1Q2 ’26
0Q3 ’26
Q4 ’23: 1; Q1 ’24: 1; Q2 ’24: 1; Q3 ’24: 1; Q4 ’24: 1; Q1 ’25: 1; Q2 ’25: 1; Q3 ’25: 1; Q4 ’25: 1; Q1 ’26: 1; Q2 ’26: 1; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Vanda Pharmaceuticals.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Vanda Pharmaceuticals
Horizon Kinetics0.0%$139k$139kTrimmed -4.6%14 qtrs

Download the holders: CSV · JSON · Markdown

About the company

Sector
Health care · Pharmaceutical Preparations
Incorporated in
Delaware
Financial year ends
31 December
Shares outstanding
60m at 30 Jul 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$33.9m2013
$110m2015
$165m2017
$227m2019
$269m2021
$193m2023
$216m2025
2013: $33.9m; 2014: $50.2m; 2015: $110m; 2016: $146m; 2017: $165m; 2018: $193m; 2019: $227m; 2020: $248m; 2021: $269m; 2022: $254m; 2023: $193m; 2024: $199m; 2025: $216m
Vanda Pharmaceuticals revenue and net income by year
YearRevenueNet income
2025$216m−$221m
2024$199m−$18.9m
2023$193m$2.5m
2022$254m$6.3m
2021$269m$33.2m
2020$248m$23.3m
2019$227m$116m
2018$193m$25.2m
2017$165m−$15.6m
2016$146m−$18.0m
2015$110m−$39.9m
2014$50.2m$20.2m
2013$33.9m−$21.1m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.